# Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

> **NCT01447225** · PHASE1 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** MM-121
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Cabazitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01447225
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2014-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2016-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01447225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01447225, "Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01447225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*